Venrock Adviser, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Venrock Adviser, LLC reported 37 stock positions worth $1.5 billion. Its top holding was Apogee Therapeutics (APGE) at 26.4% of the portfolio, followed by Ocular Therapeutix (OCUL, 7.5%) and Enliven Therapeutics (ELVN, 6.2%). Compared with Q3 2024, it opened 3 new positions, sold out of 4, added to 5 and reduced 10. The biggest buy was Praxis Precision Medicines I (PRAX, shares +40%) and the biggest sale an exit from Edgewise Therapeutics (EWTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001615982
- Portfolio Value
- $1.5B (Q4 2024)
- SEC Filing
- 0001104659-25-014110 ↗ filed Feb 14, 2025
Holdings Value
Holdings 37 stocks · $1.5B
| APGE Apogee Therapeutics Inc. | 26.40% | 8,493,321 | $384.7M | No change |
| OCUL Ocular Therapeutix Inc. | 7.48% | 12,762,462 | $109.0M | No change |
| ELVN Enliven Therapeutics Inc. | 6.22% | 4,026,331 | $90.6M | No change |
| PRAX Praxis Precision Medicines I | 5.23% | 989,985 | $76.2M | Add +40.2% |
| VRDN Viridian Therapeutics Inc. | 5.11% | 3,882,709 | $74.4M | No change |
| ORKA Oruka Therapeutics Inc. | 4.37% | 3,285,620 | $63.7M | Add +6.5% |
| SYRE Spyre Therapeutics Inc. | 4.29% | 2,685,448 | $62.5M | No change |
| PHVS Pharvaris NV | 4.24% | 3,220,130 | $61.7M | Reduce -5.2% |
| KALV Kalvista Pharmaceuticals Inc. | 3.63% | 6,249,731 | $52.9M | No change |
| DYN Dyne Therapeutics Inc. | 3.51% | 2,173,913 | $51.2M | No change |
| COGT Cogent Biosciences Inc. | 3.04% | 5,684,411 | $44.3M | Add +0.0% |
| ERAS Erasca Inc. | 2.79% | 16,216,216 | $40.7M | No change |
| DNTH Dianthus Therapeutics Inc. | 2.61% | 1,744,373 | $38.0M | No change |
| UPB Upstream Bio Inc. | 2.59% | 2,295,319 | $37.7M | New |
| ORIC Oric Pharmaceuticals Inc. | 2.43% | 4,394,527 | $35.5M | No change |
| ENGN Engene Holdings Inc. | 2.30% | 5,046,414 | $33.6M | Add +41.5% |
| MRUS Merus NV | 1.71% | 592,411 | $24.9M | Reduce -34.8% |
| ATXS Astria Therapeutics Inc. | 1.51% | 2,457,348 | $22.0M | Reduce -28.9% |
| CDTX Cidara Therapeutics Inc. | 1.41% | 765,723 | $20.6M | New |
| CGEM Cullinan Therapeutics Inc. | 1.15% | 1,379,965 | $16.8M | No change |
| FDMT 4D Molecular Therapeutics Inc. | 1.13% | 2,952,371 | $16.4M | Reduce -32.9% |
| ARTV Artiva Biotherapeutics Inc. | 1.11% | 1,609,569 | $16.2M | No change |
| MERSANA THERAPEUTICS INC | 1.01% | 10,257,790 | $14.7M | Reduce -9.4% |
| ABVX Abivax SA-ADR | 0.68% | 1,345,780 | $9.9M | No change |
| AQST Aquestive Therapeutics Inc. | 0.64% | 2,629,786 | $9.4M | Reduce -52.7% |
| APLT Applied Therapeutics Inc. | 0.59% | 9,990,591 | $8.6M | Add +1.7% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.52% | 750,000 | $7.6M | No change |
| TERN Terns Pharmaceuticals Inc. | 0.41% | 1,077,090 | $6.0M | Reduce -68.4% |
| TSHA Taysha Gene Therapies Inc. | 0.38% | 3,225,180 | $5.6M | Reduce -64.2% |
| TRVI Trevi Therapeutics Inc. | 0.36% | 1,266,457 | $5.2M | Reduce -63.0% |
| ZURA Zura Bio Ltd. | 0.35% | 2,023,166 | $5.1M | No change |
| IPSC Century Therapeutics Inc. | 0.27% | 3,957,186 | $4.0M | Reduce -26.6% |
| CASIF Casi Pharmaceuticals Inc. | 0.19% | 987,259 | $2.8M | No change |
| TNYA Tenaya Therapeutics Inc. | 0.15% | 1,555,556 | $2.2M | No change |
| TENX Tenax Therapeutics Inc. | 0.09% | 208,333 | $1.3M | No change |
| GLYCOMIMETICS INC | 0.05% | 3,000,000 | $747K | New |
| TIL Instil Bio Inc. | 0.04% | 33,177 | $633K | No change |
Portfolio Sells Q3 2024 → Q4 2024
| EWTX Edgewise Therapeutics Inc. | Sold out | 0.00% | −1.40 |
| FDMT 4D Molecular Therapeutics Inc. | Reduce -32.9% | 1.13% | −1.36 |
| TERN Terns Pharmaceuticals Inc. | Reduce -68.4% | 0.41% | −1.08 |
| AQST Aquestive Therapeutics Inc. | Reduce -52.7% | 0.64% | −0.81 |
| MRUS Merus NV | Reduce -34.8% | 1.71% | −0.67 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −0.59 |
| TSHA Taysha Gene Therapies Inc. | Reduce -64.2% | 0.38% | −0.56 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.54 |
| ATXS Astria Therapeutics Inc. | Reduce -28.9% | 1.51% | −0.49 |
| CABA Cabaletta Bio Inc. | Sold out | 0.00% | −0.39 |
| TRVI Trevi Therapeutics Inc. | Reduce -63.0% | 0.36% | −0.24 |
| IPSC Century Therapeutics Inc. | Reduce -26.6% | 0.27% | −0.21 |
| MERSANA THERAPEUTICS INC | Reduce -9.4% | 1.01% | −0.11 |
| PHVS Pharvaris NV | Reduce -5.2% | 4.24% | +0.94 |
Portfolio Buys Q3 2024 → Q4 2024
| PRAX Praxis Precision Medicines I | Add +40.2% | 5.23% | +3.10 |
| UPB Upstream Bio Inc. | New | 2.59% | +2.59 |
| CDTX Cidara Therapeutics Inc. | New | 1.41% | +1.41 |
| ENGN Engene Holdings Inc. | Add +41.5% | 2.30% | +1.07 |
| ORKA Oruka Therapeutics Inc. | Add +6.5% | 4.37% | +0.41 |
| GLYCOMIMETICS INC | New | 0.05% | +0.05 |
| COGT Cogent Biosciences Inc. | Add +0.0% | 3.04% | −0.17 |
| APLT Applied Therapeutics Inc. | Add +1.7% | 0.59% | −3.79 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $3.3B | APGE, ORKA, ERAS, SYRE, DNTH |
| Q1 2026 | 33 | $2.7B | APGE, ERAS, ORKA, SYRE, KALV |
| Q4 2025 | 27 | $2.0B | APGE, ORKA, VRDN, SYRE, KALV |
| Q3 2025 | 33 | $1.8B | APGE, MTSR, OCUL, CDTX, VRDN |
| Q2 2025 | 31 | $1.3B | APGE, OCUL, MTSR, ELVN, KALV |
| Q1 2025 | 37 | $1.2B | APGE, MTSR, OCUL, ELVN, KALV |
| Q4 2024 | 37 | $1.5B | APGE, OCUL, ELVN, PRAX, VRDN |
| Q3 2024 | 38 | $1.9B | APGE, OCUL, ELVN, VRDN, APLT |
| Q2 2024 | 35 | $1.6B | APGE, ELVN, FDMT, OCUL, DYN |
| Q1 2024 | 38 | $2.1B | APGE, FDMT, OCUL, SYRE, MRUS |